Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy


The purpose of the study is to evaluate the predictive value of 18F-fluoromisonidazol-PET (FMISO-PET), 2-18F-fluoro-2-deoxy-d-glukose-PET-CT (FDG-PET-CT), Diffusion-Weighted Magnetic Resonance Imaging (DWI-MRI) and Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) for patients with anal cancer receiving radiation therapy +/- chemotherapy (Cisplatin and 5-FU).

Full Title of Study: “18F-FMISO-PET, 18F-FDG-PET/CT, DWI-MRI and DCE-MRI Scans as Predictors of Response to Radiotherapy +/- Chemotherapy in Patients With Anal Cancer.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2012

Detailed Description

The study involves tree MRI sessions, two FDG-PET-CT sessions and one FMISO-PET session. The FMISO-PET session is presently not carried out because of delivery problems. The production of 18F-fluoromisonidazol at The Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Herlev, Denmark has not jet been approved by the Danish Medicines Agency.


  • Other: FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)
    • This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.

Arms, Groups and Cohorts

  • Anal cancer

Clinical Trial Outcome Measures

Primary Measures

  • Tumor response
    • Time Frame: 6-8 weeks post radiation
    • Primary tumor 18-F-deoxyglucose (FDG) uptake before radiation and during week 3 of radiation. Primary tumor apparent diffusion coefficient before radiation and during week 3 of radiation and 6-8 weeks post radiation Primary tumor perfusion coefficient before radiation and during week 3 of radiation and 6-8 weeks post radiation Primary tumor 18-F-Fluoromisonidazol (FMISO) uptake before radiation

Participating in This Clinical Trial

Inclusion Criteria

  • Histological confirmation of invasive primary squamous cell carcinoma of the anal canal or perianal region.
  • TNM stage T1-4, N0-3, M0-1
  • Treatment with curative intent
  • Age > 18 years
  • Able to provide informed consent

Exclusion Criteria

  • Contraindication to MRI imaging
  • Cardiac pacemaker
  • Major obesity
  • Serious claustrophobia
  • Other malignant disease (except non-melanoma skin cancer) in a period of 5 years prior to imaging study
  • Poorly regulated diabetes mellitus despite insulin
  • Pregnancy
  • Breast feeding
  • Known allergy to iv contrast agent
  • Major psychiatric illness which would prevent participation in the imaging study
  • Infectious wounds on the legs
  • Unacceptable kidney function
  • Major language difficulties which would prevent participation in the imaging study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Copenhagen University Hospital at Herlev
  • Provider of Information About this Clinical Study
    • Eva Serup-Hansen, MD, Department of Oncology, Herlev Hospital
  • Overall Contact(s)
    • Eva Serup-Hansen, MD, +4538689084,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.